Exploratory study on continuation of COVID-19 Vaccination Programme RIVM has commissioned ABDTOPconsult to do an independent exploratory study on systematic approaches to organising and incorporating the current RIVM COVID-19 Vaccination Programme.
Early indicators added to coronavirus monitoring in sewage on Coronavirus Dashboard This week, early indicators were added to the sewage measurements page on the Coronavirus Dashboard provided by the national government. These values help to clarify the measurements by indicating how serious the situation is.
Delta variant on the rise The delta variant of the coronavirus SARS-CoV-2 is occurring more and more often in the Netherlands.
COVID-19 vaccination very effective: major drop in positive tests, hospital admissions and deaths among older people People over 75 years old living at home are 82% protected against testing positive for COVID-19 from three weeks after the second vaccination.
Launch of the European project RISK-HUNT3R The new Horizon 2020 project RISK-HUNT3R: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs was launched on 1 June.
Effects of COVID-19 vaccination becoming increasingly visible In the past calendar week, there were 43% fewer hospital admissions of patients with COVID-19 compared to the week before.
Brazilian coronavirus variants (P1 and P2) found in the Netherlands Two new variants of the coronavirus SARS-CoV-2 have been found in the Netherlands, both originating from Brazil.
Invitation letter for COVID-19 vaccination for people aged 85-89 years arriving today Today, the first 50,000 people in the age group from 85-89 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
Last winter’s flu epidemic was short and mild. And then COVID-19 arrived. The flu epidemic in the winter of 2019/2020 was mild and lasted only 5 weeks.
COVID-19 vaccinations for first residents of nursing homes and small-scale residential facilities Today, the first COVID-19 vaccines will be administered to residents of nursing homes and care facilities for people with intellectual disabilities in the Netherlands.